Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?-Reference-Cited by-同舟云学术

Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?

Published:2020-11-05 Issue: Volume: Page:
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Mysona David Pierce^ORCID,Ghamande Sharad,She Jin-Xiong,Tran Lynn,Tran Paul,Rungruang Bunja J.,Chan John K.,Bae-Jump Victoria,Gehrig Paola A.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-020-09304-w.pdf

Reference22 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442 .

2. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29. https://doi.org/10.1056/nejmra041842 .

3. Morgan RJ, Armstrong DK, Alvarez RD, et al. Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(9):1134–63.

4. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53. https://doi.org/10.1056/nejmoa0908806 .

5. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57. https://doi.org/10.1016/s0140-6736(14)62223-6 .

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of minimal residual disease at upfront debulking surgery compared with complete cytoreduction after neoadjuvant chemotherapy;International Journal of Gynecologic Cancer;2024-08-07

2. Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting;Gynecologic Oncology;2022-11

3. Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision—a Literature Review;Current Oncology Reports;2022-08-15

4. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction;Diagnostics;2022-04-14

5. Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer;International Journal of Gynecologic Cancer;2022-01-12